Analysts Set Rezolute, Inc. (NASDAQ:RZLT) PT at $14.50

Rezolute, Inc. (NASDAQ:RZLT) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $14.50.

RZLT has been the subject of several research reports. Maxim Group upped their target price on Rezolute from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and issued a $17.00 target price on shares of Rezolute in a report on Thursday, September 18th. Finally, Guggenheim reissued a “buy” rating and issued a $15.00 price target on shares of Rezolute in a research report on Monday, September 22nd.

Rezolute Trading Up 2.8%

Shares of RZLT stock opened at $9.45 on Thursday. Rezolute has a twelve month low of $2.21 and a twelve month high of $10.04. The stock has a market capitalization of $858.34 million, a price-to-earnings ratio of -9.74 and a beta of 0.04. The stock has a fifty day simple moving average of $8.20 and a two-hundred day simple moving average of $5.80.

Rezolute (NASDAQ:RZLT) last issued its earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03). Research analysts predict that Rezolute will post -0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in RZLT. Jeppson Wealth Management LLC bought a new position in shares of Rezolute in the 1st quarter worth $35,000. XTX Topco Ltd bought a new position in shares of Rezolute in the 1st quarter worth $95,000. American Century Companies Inc. raised its position in shares of Rezolute by 5.2% in the 1st quarter. American Century Companies Inc. now owns 67,925 shares of the company’s stock worth $197,000 after acquiring an additional 3,334 shares in the last quarter. Pale Fire Capital SE raised its position in shares of Rezolute by 9.1% in the 1st quarter. Pale Fire Capital SE now owns 47,122 shares of the company’s stock worth $137,000 after acquiring an additional 3,935 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its position in shares of Rezolute by 7.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,700,000 shares of the company’s stock worth $4,930,000 after acquiring an additional 125,000 shares in the last quarter. 82.97% of the stock is owned by institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.